BioMEANDER (Q3989231): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Adding German translations) |
(Removed claims) |
||
| Property / beneficiary name (string) | |||
| Property / beneficiary name (string): Lead Pharma Holding / rank | |||
| Property / beneficiary | |||
| Property / beneficiary: Q3986142 / rank | |||
Revision as of 09:28, 16 December 2021
Project Q3989231 in Netherlands
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BioMEANDER |
Project Q3989231 in Netherlands |
Statements
306,823.43 Euro
0 references
1,998,722.03 Euro
0 references
15.351 percent
0 references
1 July 2017
0 references
30 June 2020
0 references
51°49'29.71"N, 5°49'23.30"E
0 references
6534 AT
0 references
7500 AL
0 references
6700 AG
0 references
7500 AE
0 references
Binnen het BioMeander project wordt een zeer gevoelig screening- en detectieplatform, gebaseerd op een asymmetrische Mach-Zehnder interferometer, voor biologische testen ontwikkeld.De gezamenlijke technische innovaties van Surfix en LioniX leide... (Dutch)
0 references
Within the BioMeander project, a highly sensitive screening and detection platform, based on an asymmetric Mach-Zehnder interferometer, is being developed for biological testing.The joint technical innovations of Surfix and LioniX... (English)
15 December 2021
0 references
Dans le cadre du projet BioMeander, une plateforme de dépistage et de détection hautement sensible, basée sur un interféromètre Mach-Zehnder asymétrique, est en cours de développement pour les tests biologiques.Les innovations techniques conjointes de Surfix et LioniX... (French)
15 December 2021
0 references
Innerhalb des BioMeander-Projekts wird eine hochempfindliche Screening- und Detektionsplattform, basierend auf einem asymmetrischen Mach-Zehnder-Interferometer, für biologische Tests entwickelt.Die gemeinsamen technischen Innovationen von Surfix und LioniX... (German)
15 December 2021
0 references
Identifiers
OP-2014-2023-Oost-PROJ-00697
0 references